Pharmacological JNK inhibition (with SP600125), markedly improved insulin-mediated vasodilation and vascular endothelial function, further suggesting JNK as a potential target in obesity-related vascular diseases [81]. This evidence concerns the gene MAPK8 and obesity due to melanocortin 4 receptor deficiency.